Takumitsu Akutsu's Contact Details

Takumitsu Akutsu's Company Details

CUORiPS Inc.

Chuo, Tokyo, Japan • 3 Employees
Research

CUORiPS Inc. is a start-up company established in March 2017, to develop and commercialize regenerative medicines/cell therapy products for severe heart failure, based on a technology platform using iPS cell-derived cardiomyocytes.Using a state-of-the-art iPS-related technology platform from Osaka University, we aim to treat various types of heart failure, which is the largest cause of death in the U.S. and Europe, and 2nd largest cause of death in JapanStrong collaboration with Osaka University, one of the best academia in Regenerative Medicine who achieved First-In-Human iPS-derived cardiomyocytes therapy clinical trialThrough our original technology on cell culture and process development in our Cell Processing Center "CLiC-1", we are ready to commercialize clinical-grade iPSC-derived Cell Therapy products to the market with Japan Quality.Utilizing diverse partnerships with various firms, we have access to miscellaneous technology, expertise, resources, and knowhow, which can accelerate our product development and commercialization